A total of 123 ET patients received IFN-2b therapy with JAK2V617F positive or negative mutation ; and 136 PV patients with JAK2V617F ( + ) received IFN-2b or hydroxyurea ( HU ) therapy according to random number assignment ( ages 18-65 years old ) .